INMB
Price
$4.58
Change
-$0.40 (-8.03%)
Updated
Dec 18, 04:59 PM (EDT)
71 days until earnings call
WINT
Price
$0.36
Change
-$0.02 (-5.26%)
Updated
Dec 18, 04:58 PM (EDT)
Ad is loading...

INMB vs WINT

Header iconINMB vs WINT Comparison
Open Charts INMB vs WINTBanner chart's image
INmune Bio
Price$4.58
Change-$0.40 (-8.03%)
Volume$2.3K
CapitalizationN/A
Windtree Therapeutics
Price$0.36
Change-$0.02 (-5.26%)
Volume$2.21K
CapitalizationN/A
INMB vs WINT Comparison Chart
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WINT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. WINT commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and WINT is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (INMB: $4.98 vs. WINT: $0.38)
Brand notoriety: INMB and WINT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 88% vs. WINT: 24%
Market capitalization -- INMB: $110.42M vs. WINT: $3.42M
INMB [@Biotechnology] is valued at $110.42M. WINT’s [@Biotechnology] market capitalization is $3.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileWINT’s FA Score has 1 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • WINT’s FA Score: 1 green, 4 red.
According to our system of comparison, WINT is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 5 TA indicator(s) are bullish while WINT’s TA Score has 4 bullish TA indicator(s).

  • INMB’s TA Score: 5 bullish, 5 bearish.
  • WINT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, WINT is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -8.46% price change this week, while WINT (@Biotechnology) price change was +2.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

INMB is expected to report earnings on Feb 27, 2025.

WINT is expected to report earnings on May 17, 2023.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INMB($110M) has a higher market cap than WINT($3.33M). INMB YTD gains are higher at: -55.773 vs. WINT (-97.064). WINT has higher annual earnings (EBITDA): -10.85M vs. INMB (-41.55M). INMB has more cash in the bank: 33.6M vs. WINT (1.8M). INMB has less debt than WINT: INMB (2.91M) vs WINT (3.38M). INMB has higher revenues than WINT: INMB (42K) vs WINT (0).
INMBWINTINMB / WINT
Capitalization110M3.33M3,307%
EBITDA-41.55M-10.85M383%
Gain YTD-55.773-97.06457%
P/E RatioN/A0.83-
Revenue42K0-
Total Cash33.6M1.8M1,864%
Total Debt2.91M3.38M86%
FUNDAMENTALS RATINGS
INMB vs WINT: Fundamental Ratings
INMB
WINT
OUTLOOK RATING
1..100
31
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
6497
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WINT's Valuation (61) in the Biotechnology industry is in the same range as INMB (90). This means that WINT’s stock grew similarly to INMB’s over the last 12 months.

INMB's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as WINT (100). This means that INMB’s stock grew similarly to WINT’s over the last 12 months.

INMB's SMR Rating (98) in the Biotechnology industry is in the same range as WINT (98). This means that INMB’s stock grew similarly to WINT’s over the last 12 months.

INMB's Price Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for WINT (97). This means that INMB’s stock grew somewhat faster than WINT’s over the last 12 months.

WINT's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for INMB (100). This means that WINT’s stock grew significantly faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBWINT
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 22 days ago
74%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WINT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EMPYF0.260.02
+7.96%
Empress Royalty Corp.
MGDDY16.880.01
+0.06%
CIE GENERALE DES ETABLISSEMENTS MICHELIN SA CLERMONT-FERRAND
GLNCY9.14-0.11
-1.19%
Glencore Plc
ZLNDY17.73-0.24
-1.34%
ZALANDO SE
ZPTAF3.69-0.05
-1.34%
Surge Energy, Inc.

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with MDGL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
-1.97%
MDGL - INMB
41%
Loosely correlated
-1.58%
ORMP - INMB
38%
Loosely correlated
-1.67%
AXON - INMB
37%
Loosely correlated
-2.09%
PRME - INMB
34%
Loosely correlated
-3.00%
CYTK - INMB
34%
Loosely correlated
-2.53%
More

WINT and

Correlation & Price change

A.I.dvisor indicates that over the last year, WINT has been loosely correlated with MLEC. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if WINT jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WINT
1D Price
Change %
WINT100%
-3.77%
MLEC - WINT
49%
Loosely correlated
-5.74%
DVHGF - WINT
37%
Loosely correlated
N/A
INMB - WINT
31%
Poorly correlated
-1.97%
ESLA - WINT
29%
Poorly correlated
-3.15%
CDTX - WINT
27%
Poorly correlated
-1.93%
More